Posted by Michael Wonder on 01 Sep 2022
ACE publishes another tranche of technology guidances (August 2022)
31 August 2022 - Six technology guidance documents were published yesterday.
The technology guidance documents are for:
- Cancer supportive care medicines
- Tyrosine kinase inhibitors for patients with MET mutation positive metastatic non-small-cell lung cancer
- Gemtuzumab ozogamicin for patients with untreated de novo CD33 positive acute myeloid leukaemia
- Nivolumab for patients with gastro-oesophageal cancer
- SGLT-2 inhibitors for patients with chronic heart failure with a reduced ejection fraction and patients with chronic kidney disease
- Cabozantinib maleate for use in combination with nivolumab for the treatment of patients with previously untreated advanced renal cell carcinoma
